ImmunityBio Executive Compensation Details Released
Ticker: IBRX · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | DEF 14A |
| Filed Date | Apr 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, sec-filing
Related Tickers: IBIO
TL;DR
IBIO proxy statement out, exec comp details for 2024 are in.
AI Summary
ImmunityBio, Inc. filed a DEF 14A on April 30, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to both principal executive officers (PEO) and non-PEO/NEO members, with details on year-end fair values and changes in fair value for outstanding and unvested awards.
Why It Matters
This filing provides transparency into how ImmunityBio compensates its top executives, which can influence investor perception and the company's ability to attract and retain talent.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the specifics of executive compensation can sometimes signal company performance or future strategic decisions.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for executive compensation)
- 20250430 — Filing Date (Date the DEF 14A was filed with the SEC)
Key Players & Entities
- ImmunityBio, Inc. (company) — Filer of the DEF 14A
- NantKwest, Inc. (company) — Former company name
- Conkwest, Inc. (company) — Former company name
- ZelleRx Corp (company) — Former company name
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide detailed information regarding the solicitation of proxies for the company's annual meeting of stockholders, including executive compensation details.
What fiscal year does the executive compensation information primarily cover?
The executive compensation information primarily covers the fiscal year ending December 31, 2024.
What types of equity awards are detailed in the filing?
The filing details equity awards granted to PEO (Principal Executive Officer) and Non-PEO/NEO (Non-Principal Executive Officer/Named Executive Officer) members, including their year-end fair values and changes in fair value.
When was ImmunityBio, Inc. previously known by other names?
ImmunityBio, Inc. was formerly known as NantKwest, Inc. (effective 20150713), Conkwest, Inc. (effective 20140416), and ZelleRx Corp (effective 20050504).
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2836, categorized under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding ImmunityBio, Inc. (IBRX).